Hefu China (603122) is a new issue of the Shanghai main board of the stock, the time of the application for the purchase of Hefei China is February 7, this stock in this week's main board of the stock of the issuance of a small amount of 99,513,200 shares, the issuance price of 4.19 yuan, the industry price-earnings ratio of 18.76. The issuance price is low compared to other stocks, however, the issuance price is not as low as the price of the stock, but the price of the stock. The issue price is low compared to other stocks, but it doesn't mean that the stock will yield less, so it's important to make an aggressive bid.
The issuer is a channel provider in the medical distribution field and has the core competence of long-term mutual benefit and cooperation***winning with domestic and foreign reagent and consumable and medical equipment manufacturers, major agents and medical institutions.
Different from the traditional agency model where the original manufacturers restrict the agents' sales area and exclude the cooperation of competing products, the issuer is not subject to the above constraints and at the same time has established cooperative relationships with multi-branded suppliers, based on which the issuer's in-vitro diagnostic product pooling business is currently able to provide customers with in-vitro diagnostic reagents and consumables with a full range of 17,000 items from more than 1,000 different manufacturers. consumables from more than 1,000 different manufacturers.
The Issuer has established cooperative relationships covering the major in vitro diagnostic reagent items of more than 100 tertiary hospitals, and provides them with comprehensive in vitro diagnostic product centralized purchasing services, which saves the hospitals the cost of purchasing reagents and consumables by reducing the number of agent layers between the original manufacturers and the medical institutions. Meanwhile, based on its extensive experience in intensive services, the Issuer dispatches specialists to its major customers to station and assist in inventory management, procurement volume estimation, departmental professional training and information construction.
The Issuer's medical product distribution business is based on the agency of original equipment of foreign innovative medical technologies, mainly for medical institutions in Greater China. The core management team of the issuer mainly comes from the management team of multinational medical companies in Greater China, and understands the demand of the medical market and has the ability to judge the market prospect of the products. Over the past ten years, the Issuer has successfully represented and introduced a number of foreign advanced medical equipment, including Accuray, TearScience, Viewray, etc., and has won the awards of the best global agent and best performance granted by the original manufacturers during the period of cooperation, with the relevant agent products covering more than 70 hospitals, and providing long-term maintenance services.
The issuer's medical product distribution business also includes the provision of distribution services in the medical product channel network, which is oriented towards embedding in the channel network dominated by the upstream original manufacturers and their major agents, and actively utilizing the channel advantages.